interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Bimatoprost

Generic competition · all medicines · read 12 November 2026

Is there a generic of Bimatoprost, and who makes it?

Bimatoprost appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 9 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 5.9 and 13.9 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Bimatoprost4 dosage-form groups in the Orange Book
9generic makers listed
  1. Bimatoprost appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 9 generic makers listed as marketed across them.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 5.9 and 13.9 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution/Drops, Ophthalmic

Four or more generic makers listed

Brand listed as marketed: Lumigan. 9 generic makers with 9 generic products listed as marketed; the first generic approval is dated 20 February 2015.

200020052010201520202025203009brand 2001Sandoz Inc, first approval 5 May 2015Apotex Inc, first approval 20 July 2015Gland Pharma Ltd, first approval 22 March 2019Alembic Pharmaceuticals Ltd, first approval 12 April 2019Somerset Therapeutics Llc, first approval 19 June 2019Micro Labs Ltd, first approval 8 September 2020Eugia Pharma Specialities Ltd, first approval 6 October 2022Mankind Pharma Ltd, first approval 17 March 2025Amneal Eu Ltd, first approval 22 September 2025data datePatent 7851504 listed to expire 13 June 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Sandoz Inc5 May 20151
Apotex Inc20 July 20151
Gland Pharma Ltd22 March 20191
Alembic Pharmaceuticals Ltd12 April 20191
Somerset Therapeutics Llc19 June 20191
Micro Labs Ltd8 September 20201
Eugia Pharma Specialities Ltd6 October 20221
Mankind Pharma Ltd17 March 20251
Amneal Eu Ltd22 September 20251

Patents and exclusivities still listed

  • 13 June 2027Patent 7851504 drug substance

Solution/Drops, Topical

One to three generic makers listed

Brand listed as marketed: Latisse. 2 generic makers with 2 generic products listed as marketed; the first generic approval is dated 1 December 2014.

20052010201520202025203002brand 2008Sandoz Inc, first approval 19 April 2016Alembic Pharmaceuticals Ltd, first approval 21 January 2020data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Sandoz Inc19 April 20161
Alembic Pharmaceuticals Ltd21 January 20201

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Gel, Ophthalmic

Brand listed, no generic listed as marketed

Brand listed as marketed: Zolymbus. No generic is listed as marketed.

2020202520302035204001brand 2025data datePatent 10314780 listed to expire 8 June 2036Exclusivity NDF to 9 September 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 9 September 2028Exclusivity NDF Zolymbus
  • 8 June 2036Patent 10314780 drug product

Implant, Ophthalmic

Brand listed, no generic listed as marketed

Brand listed as marketed: Durysta. No generic is listed as marketed.

202020252030203501brand 2020data datePatent 10441543 listed to expire 19 December 2026Patent 9149428 listed to expire 19 December 2026Patent 8206737 listed to expire 7 April 2027Patent 7799336 listed to expire 24 April 2029Patent 8629185 listed to expire 15 July 2031Patent 9980974 listed to expire 31 October 2034Patent 9492316 listed to expire 31 October 2034
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 19 December 2026Patent 10441543 drug product
  • 19 December 2026Patent 9149428 drug product
  • 7 April 2027Patent 8206737
  • 24 April 2029Patent 7799336 drug product
  • 15 July 2031Patent 8629185 drug substance
  • 31 October 2034Patent 9980974
  • 31 October 2034Patent 9492316 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.